DGIdb - RITONAVIR Drug Record

RITONAVIR chembl:CHEMBL163 Approved

Alternate Names:

NSC-693184
RITONAVIR
ABT-538
RITONAVIR RELATED COMPOUNDS MIXTURE
ABBOTT-84538
A-84538
NORVIR
ABT 538
NORVIR®
RITONAVIRUM
N-[(1S,3S,4S)-1-BENZYL-3-HYDROXY-5-PHENYL-4-{[(1,3-THIAZOL-5-YLMETHOXY)CARBONYL]AMINO}PENTYL]-N~2~-(METHYL{[2-(1-METHYLETHYL)-1,3-THIAZOL-4-YL]METHYL}CARBAMOYL)-L-VALINAMIDE
chemidplus:155213-67-5
chembl:CHEMBL163
drugbank:00503
rxcui:85762
pubchem.compound:392622

Drug Info:

(2 More Sources)

Publications:

Gisolf et al., 2000, Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy., J. Acquir. Immune Defic. Syndr.
Li F et al., 2012, CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir., Drug Metab Dispos
Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Greenblatt DJ et al., 2015, Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies., Br J Clin Pharmacol
Tong L et al., 2007, Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro., Antimicrob Agents Chemother
Liu X et al., 2017, Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus., Pharmacotherapy
Tsai MS et al., 2017, Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study., J Microbiol Immunol Infect
Bonora S et al., 2015, Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)., J Antimicrob Chemother
Avihingsanon A et al., 2015, Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia., J Acquir Immune Defic Syndr
Nishijima T et al., 2014, Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study., J Antimicrob Chemother
D'Avolio A et al., 2014, Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms., J Antimicrob Chemother
Coelho AV et al., 2013, ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients., J Clin Pharmacol
Lubomirov R et al., 2011, Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study., J Infect Dis
Park WB et al., 2010, Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency., Clin Infect Dis
Ma Q et al., 2007, Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV., Pharmacogenomics
Rodríguez-Nóvoa S et al., 2007, Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia., AIDS
Hogg M et al., 1991, Chloride influx in human leucocytes: a triple-isotope technique for the assessment of chloride transporters., Clin Sci (Lond)
Rodríguez Nóvoa et al., 2006, Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1., Clin. Infect. Dis.
Haas DW et al., 2003, MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study., J Acquir Immune Defic Syndr
da Rocha IM et al., 2015, Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort., Pharmacogenet Genomics
Equils et al., 2004, Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation., Antimicrob. Agents Chemother.
Arnedo M et al., 2007, Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy., Pharmacogenet Genomics
Tarr PE et al., 2005, Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders., J Infect Dis
Perloff et al., 2001, Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line., J Pharm Sci
Faucette et al., 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers., Drug Metab. Dispos.
Smith CM et al., 2005, Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers., J Biochem Mol Toxicol
Lankisch TO et al., 2006, Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype., Hepatology
Ehmann F et al., 2014, European Medicines Agency initiatives and perspectives on pharmacogenomics., Br J Clin Pharmacol
Eagling et al., 1997, Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir., Br J Clin Pharmacol

RITONAVIR APOC3

Interaction Score: 6.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15809899

Sources:
PharmGKB
RITONAVIR UGT1A7

Interaction Score: 0.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17058217

Sources:
PharmGKB
RITONAVIR TLR4

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15388451

Sources:
NCI
RITONAVIR APOE

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17700364 15809899

Sources:
PharmGKB
RITONAVIR CXCL10

Interaction Score: 0.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11141242

Sources:
NCI
RITONAVIR UGT1A3

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17058217

Sources:
PharmGKB
RITONAVIR CYP2E1

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9278209

Sources:
NCI
RITONAVIR ABCC1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11745741 23996099

Sources:
NCI PharmGKB
RITONAVIR ABCB1

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17664327 28718515 26857335 26174719 25622064 25151207 24997317 23996099 21288825 20504240 17324111 17148966 1655344 16355344 14600574

Sources:
DTC PharmGKB
RITONAVIR IFNL3

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

Combination therapy Dasabuvir,Ombitasvir,Paritaprevir,Ritonavir

Combination therapy Ombitasvir,Paritaprevir,Ritonavir

PMIDs:
None found

Sources:
FDA
RITONAVIR CYP2B6

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14977870

Sources:
NCI
RITONAVIR ABCC2

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26287941

Sources:
PharmGKB
RITONAVIR NR1I2

Interaction Score: 0.09

Interaction Types & Directionality:

activator (activating)

Interaction Info:

PMIDs:
14977870 15849716

Sources:
PharmGKB
RITONAVIR NPSR1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
RITONAVIR CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RITONAVIR KAT2A

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
RITONAVIR CYP3A4

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
21953914 21393461 9187528 25923589

Sources:
DTC PharmGKB
RITONAVIR CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24433361

Sources:
PharmGKB
RITONAVIR VDR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DTC: RITONAVIR

Version: 02-September-2020

Alternate Names:

CHEMBL163 ChEMBL Drug ID

Drug Info:

Publications:

Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos

Li F et al., 2012, CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir., Drug Metab Dispos

Tong L et al., 2007, Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro., Antimicrob Agents Chemother

NCI: RITONAVIR

Version: 14-September-2017

Alternate Names:

C1609 NCI drug code

Drug Info:

Publications:

Gisolf et al., 2000, Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy., J. Acquir. Immune Defic. Syndr.

Equils et al., 2004, Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation., Antimicrob. Agents Chemother.

Faucette et al., 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers., Drug Metab. Dispos.

PharmGKB: ritonavir

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Greenblatt DJ et al., 2015, Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies., Br J Clin Pharmacol

da Rocha IM et al., 2015, Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort., Pharmacogenet Genomics

Arnedo M et al., 2007, Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy., Pharmacogenet Genomics

TTD: Ritonavir
- Version: 2020.06.01
Alternate Names:

D0ZU9R TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL163
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Ritonavir
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Combination therapy	Dasabuvir,Ombitasvir,Paritaprevir,Ritonavir
Combination therapy	Ombitasvir,Paritaprevir,Ritonavir

RITONAVIR Drug Record

RITONAVIR chembl:CHEMBL163 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15809899

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17058217

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15388451

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17700364 15809899

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11141242

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17058217

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9278209

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11745741 23996099

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17664327 28718515 26857335 26174719 25622064 25151207 24997317 23996099 21288825 20504240 17324111 17148966 1655344 16355344 14600574

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Combination therapy Dasabuvir,Ombitasvir,Paritaprevir,Ritonavir Combination therapy Ombitasvir,Paritaprevir,Ritonavir

PMIDs: None found

Sources: FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14977870

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26287941

Sources: PharmGKB

Interaction Types & Directionality: activator (activating)

Interaction Info:

PMIDs: 14977870 15849716

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 21953914 21393461 9187528 25923589

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24433361

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

n/a

PMIDs:
15809899

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17058217

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15388451

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17700364 15809899

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11141242

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17058217

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9278209

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11745741 23996099

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17664327 28718515 26857335 26174719 25622064 25151207 24997317 23996099 21288825 20504240 17324111 17148966 1655344 16355344 14600574

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Combination therapy Dasabuvir,Ombitasvir,Paritaprevir,Ritonavir

Combination therapy Ombitasvir,Paritaprevir,Ritonavir

PMIDs:
None found

Sources:
FDA

Interaction Types & Directionality:

n/a

PMIDs:
14977870

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
26287941

Sources:
PharmGKB

Interaction Types & Directionality:

activator (activating)

PMIDs:
14977870 15849716

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
21953914 21393461 9187528 25923589

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24433361

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

CHEMBL163 ChEMBL Drug ID

Alternate Names:

C1609 NCI drug code

Alternate Names:

D0ZU9R TTD Drug ID